Category Archives: PRNews

PRNews

Professor Brian Wilson Receives IPA Excellence Award In Photodiagnostic Research

COIMBRA, Portugal, July 11, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Professor Brian Wilson was the recipient of the 2017 EXCELLENCE AWARD IN PHOTODIAGNOSTIC RESEARCH.


Professor Brian Wilson

Dr. Brian Wilson is Professor of Medical Biophysics at Princess Margaret Cancer Centre/University Health Network, University of Toronto, Canada. He is a well-known expert and leader in the field of PDT and Photodiagnostics, internationally recognized for his pioneering research into various optic tools that can be used for minimally-invasive cancer treatment, and early diagnosis and optically-guided cancer therapeutics. He holds several awards in biomedical optics (Mark Award, NIH Translational Research Award, Michael S. Feld Award and Britton Chance Award) and in cancer research (Robert L. Noble Prize).

In 1981, Dr. Wilson initiated translational research and collaborative clinical trials of photodynamic therapy for brain, prostate and gastrointestinal cancers. Dr. Wilson leads a world-renowned R&D program in optics-based biomedical applications, with a primary translational/clinical focus. He has driven the development of fluorescence and other endoscopic imaging techniques – particularly in Barrett’s esophagus and colon cancer – and more recently has developed optical imaging to guide surgery that is being evaluated in clinical trials for head and neck, prostate and brain cancers. In the last few years, his research has expanded to include development of photonic nanoparticles in cancer treatment, diagnosis and research. Dr. Wilson has published over 350 peer-reviewed papers in basic, translational and clinical research. With several international Visiting Appointments (Harvard, USA; Saõ Paulo, Brazil; Fujian, China; Western Australia), Dr. Wilson is involved in many national and international collaborations. Dr. Wilson has trained more than 50 graduate students, post-doctoral and clinical fellows, many of whom remain in biomedical optics, cancer research and practice worldwide. He also has worked with many companies nationally and internationally in translating optical technologies into clinical practice.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies.  The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).  

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

For more information, please contact: ipasecretary@internationalphotodynamic.com

PRNews

Burjeel Hospital Wins ‘2017 UAE Emerging Medical Tourism Service Provider of the Year – Hospital Category’ Award at the 2017 Frost & Sullivan Middle East Best Practices Awards

DUBAI, United Arab Emirates, July 6, 2017 /PRNewswire/ — Burjeel Hospital (A unit of VPS Healthcare) was named ‘2017 UAE Emerging Medical Tourism Service Provider of the Year- Hospital Category‘ at the 2017 Frost & Sullivan Middle East Best Practices Awards Banquet held on 24th May at Atlantis, The Palm in Dubai.


Dr. Raja Gujju, Chief Operating Officer & Dr.Nabil Debouni, Medical Director, Burjeel Hospital receives the 2017 UAE Emerging Medical Tourism Service Provider of the Year – Hospital Category Award from Mr. Jamal Ramadhan Bin Marghoob, Director Marketing & Corporate Communications, from Dubai Airport Freezone in presence of Mr. Sandeep Sinha, Vice President, Transformational Health Practice, Frost & Sullivan

Burjeel Hospital Abu Dhabi is an emerging medical tourism service provider in the UAE. It caters to the growing medical needs of the UAE and GCC by offering high quality care in all medical specialties. The top five specialties in Burjeel Hospital Abu Dhabi, for international patients, include obstetrics, gynecology, orthopedics, neonatology, general surgery and gastroenterology. It offers special packages for cesarean section, bariatric surgery and hip replacement. Established in 2012, the hospital is currently expanding its operational beds to accommodate the growing needs of the local and international populace.

“We are truly honored to be recognized in this category by Frost & Sullivan this year. The award underlines our commitment as an organization to provide the best healthcare in the region and significantly contribute in enhancing the area of medical tourism in the UAE,” said Dr. Raja Gujju, Chief Operating Officer, Burjeel Hospital – Abu Dhabi.

Congratulating Burjeel Hospital Abu Dhabi on the award, Mr. Sandeep Sinha, Vice President, Transformational Health Practice, Frost & Sullivan said, “2016 has been a very successful year for Burjeel Hospital Abu Dhabi. The company’s international patient department contributed 34 percent to the total revenue of the hospital with an inflow of more than 8,000 international patients. The hospital not only provides world-class tertiary healthcare in the region, it also enhances the patient’s experience by managing their logistic needs, including visa and travel arrangements, hotel stays, dietary services, religious needs and airport transfer, thus delivering a stress-free experience. Its growth, unique services, marketing initiatives, technical advancements and the compassionate patient-centric approach are some of the key factors which have contributed to its leading position in the region.”

Frost & Sullivan Awards recognize companies across regional and global markets for outstanding achievement and performance in a range of regional and global markets for superior leadership, technological innovation, customer service, strategic product development among others.

Frost & Sullivan’s robust research methodology represents the analytical rigor of our research process. It offers a 360-degree-view of industry challenges, trends, and issues by integrating all 7 research methodologies. Too often, companies make important growth decisions based on a narrow understanding of their environment, leading to errors of both omission and commission. Successful growth strategies are founded on a thorough understanding of market, technical, economic, financial, customer, best practices, and demographic analyses. The integration of these research disciplines into the 360-degree research methodology provides an evaluation platform for benchmarking industry players and for identifying those performing at best-in-class levels.

About Burjeel Hospital

Burjeel Hospital is Abu Dhabi’s premier private healthcare facility providing world-class, specialized and superior healthcare complemented by a warm and personalized human touch to the growing population of the emirate of Abu Dhabi.

A unit of the VPS Healthcare, Burjeel Hospital opened for patients in April 2012 as a Tertiary hospital under the auspices of the Health Authority for Abu Dhabi.  At the core of the organization is a team of exceptionally skilled and highly experienced health professionals, collaborating as multidisciplinary teams with guests and their families as the main focus, to provide the best healthcare experience. 

Burjeel Hospital received the prestigious Joint Commission International (JCI) accreditation in June 2013 – 15 months after starting operations and the hospital was granted JCI Re-accreditation in Aug 2016. Currently, the hospital is affiliated with some of the world’s best healthcare institutions for its centers of excellence and is now becoming a renowned center of referral for Cardiovascular, Orthopedics, Ophthalmology, Pediatrics, Obstetrics and Gynecology, Reproductive Medicine, Oncology and many more specialties handling complex laparoscopic and minimally invasive surgeries. The hospital has full-fledged pharmacy, laboratory, and radiology units to serve guests at any time of the day. Burjeel also houses a restaurant and a coffee shop, serving the finest and healthiest cuisines from across the world. Combining all-round specialization and expertise with most advanced technology, Burjeel offers the best in diagnostic, curative, as well as preventive aspects of healthcare.

For more details, visit the website at www.burjeel.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

For Frost & Sullivan

Anita Chandhoke
Corporate Communications
C: +91 99161 33311
P: +91.80.6702 8020
E: achandhoke@frost.com
http://www.frost.com

For Burjeel Hospital

Joanne Rico
Marketing and Business Development Department
C: +971 8841 669
P: +971 2 508 5656
E: joanne.rico@burjeel.com 
www.burjeel.com

Photo – http://mma.prnewswire.com/media/530941/Burjeel_Hospital_Frost_Sullivan_Award.jpg

PRNews

INSTI HIV Self Test Receives Global Fund Classification for Procurement

bioLytical’s INSTI approved by UNITAID and Global Fund expert panel

RICHMOND, British Columbia, July 6, 2017 /PRNewswire/ — bioLytical Laboratories, a world leader in rapid infectious disease tests, is pleased to announce that its INSTI HIV Self Test has been designated by the Global Fund as eligible for procurement by purchasing entities entitled to access Global Fund and UNITAID resources.


INSTI HIV Self Test Receives Global Fund Classification for Procurement

The INSTI HIV Self Test is now eligible for procurement by organizations accessing Global Fund and/or UNITAID funding for their HIV self-test pilot programs that empower individuals to take control of their own health.

“We are very pleased to be awarded this designation by the Global Fund’s Expert Review Panel” said Livleen Veslemes, Chief Operating Officer of bioLytical Laboratories. “In anticipation of significant global demand for a blood-based self-test, we placed a second automated bottling line into service earlier this year to augment the test device production equipment which is designed to produce 1 test per second. We are also investing further into process scale-up, facility optimization, warehouse expansion and evaluating automation of packaging to meet projections from international markets while maintaining the highest product quality standards.”

The Global Fund’s Expert Review Panel for Diagnostics is a mechanism to expedite access to innovative diagnostic products for one year. During this period, bioLytical will pursue World Health Organization prequalification along with approval from another stringent regulatory agency, such as CE marking, of its self-test version for low and middle income countries (LMICs).

Being a market leader in point-of-care HIV tests in major markets across Europe and North America, healthcare providers trust the INSTI brand because it delivers the accurate information and provides instant results for their patients. The INSTI product range is built on a strong foundation of peer-reviewed science and regulatory approvals and supported by over 14 years of expertise, quality, and innovation in medical diagnostics.

About bioLytical Laboratories Inc.

bioLytical Laboratories Inc. is a privately owned Canadian company engaged in the research, development and commercialization of rapid, point of care in vitro medical diagnostics using its proprietary INSTI technology platform.  With a world-wide footprint of regulatory approvals including US FDA approval, Health Canada approval and CE mark, bioLytical markets and sells its INSTI HIV test globally and INSTI HIV/Syphilis Multiplex test in Europe.  The INSTI product line provides highly accurate test results in 60 seconds or less, far faster than the 15-20 minutes required for competitors’ tests based on lateral flow technology.  bioLytical has an active R&D program with a pipeline that includes tests for diseases such as Zika, Hepatitis C and Ebola, among others.  The company also provides contract services to adapt the INSTI platform to meet custom functional and technical diagnostic testing requirements.  For more information, please visit www.biolytical.com.

Contact: Robert Mackie, info@biolytical.com, +1-604-204-6784

Photo – http://mma.prnewswire.com/media/530919/bioLytical_INSTI_HIV_Self_Test.jpg

PRNews

Accomplished technology executive Chris Veator is latest addition to Clarivate Analytics, leading its MarkMonitor business

PHILADELPHIA, July 6, 2017 /PRNewswire/ — Clarivate Analytics, a global leader in providing trusted insights and analytics to accelerate the pace of innovation, today announced that Chris Veator joined the company as President of its MarkMonitor business. Veator will lead the global MarkMonitor team from its San Francisco office.


Chris Veator joins Clarivate Analytics to lead its MarkMonitor business

MarkMonitor is the global leader in online brand protection, and provides advanced technology and expertise that protects the revenues and reputations of the world’s foremost brands. It leads the industry in providing domain management, anti-piracy and anti-fraud solutions to more than half of the Fortune 100.

“With the company’s focus on innovation, I’m excited to join at a time when Clarivate is making a major investment in new technology and analytics that is already in production with 100 MarkMonitor customers,” said Veator.

Prior to this role, Veator was President of Metrostudy, a Hanley Wood company, where he oversaw the rapid growth of the real estate and construction information business. Prior to that, he was Executive Vice President and Global Head of Intellectual Property Services at Thomson Reuters. Veator has also held senior executive roles at CPA Global, OpenText and was the founder and CEO of Artesia Technologies – a Digital Asset Management software company.

“Chris is a high-energy executive and an exciting addition to our team as we focus on building Clarivate Analytics and accelerating its growth,” said Jay Nadler, CEO of Clarivate Analytics. “He has had success both as an entrepreneur and as an “intrapreneur”, driving growth of new initiatives within a corporate setting. I look forward to what Chris will bring to the MarkMonitor business.”

Clarivate Analytics

Clarivate™ Analytics accelerates the pace of innovation by providing trusted insights and analytics to customers around the world, enabling them to discover, protect and commercialize new ideas faster. Formerly the Intellectual Property and Science business of Thomson Reuters, we own and operate a collection of leading subscription-based businesses focused on scientific and academic research, patent analytics and regulatory standards, pharmaceutical and biotech intelligence, trademark protection, domain brand protection and intellectual property management. Clarivate™ Analytics is now an independent company with over 4,000 employees, operating in more than 100 countries and owns well‐known brands that include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor® and Techstreet™, among others. For more information, please visit clarivate.com.

Media Contact
Heidi Siegel
Clarivate Analytics
Director, External Relations
+1 215 823 5646 (o)
+1 215 356 4504 (m)
heidi.siegel@clarivate.com

PRNews

Merck Awards EUR1.25 Million to Research Projects Through its 2017 Grant for Fertility Innovation (GFI)

DARMSTADT, Germany, July 5, 2017 /PRNewswire/ —

  • Two projects are awarded funds to advance the fertility field 
  • Professor Lunenfeld honored with Merck Lifetime Achievement Award 
  • The company is committed to driving innovation through evolving the product portfolio and investing in potential breakthrough research 

Merck, a leading science and technology company, today announced its commitment to award EUR1.25 million to research projects in the field of fertility, supporting the advancement of medical science through the Grant for Fertility Innovation (GFI) in 2017. Launched as the first of the Merck Grants for Innovation in 2009, Merck’s GFI is providing encouragement for innovation and support for scientists to realize projects that could potentially lead to the next breakthrough in the fertility treatment area. This year, the GFI Award Ceremony included the announcement of the Merck Lifetime Achievement Award in Fertility Innovation.

To recognize Merck’s belief in progress through innovation, the GFI awardees were revealed in a ceremony at the European Society of Human Reproduction and Embryology (ESHRE), currently taking place in Geneva, Switzerland. The winning projects truly reflect the global nature of the program, ranging from research in Italy to Brazil.

Professor Bruno Lunenfeld, a speaker at the GFI 2017 ceremony, was honored with the Merck Lifetime Achievement Award for his revolutionary work within the fertility field since 1954. At the ceremony he provided an overview on the discovery of human gonadotropins from postmenopausal urine.

“Professor Lunenfeld’s pioneering achievements in the field of fertility are a huge inspiration to us at Merck. It is highly motivating to consider the breadth of his contributions. For more than 60 years now, his expertise and experience have greatly contributed to our efforts to improve the quality of patient care,” said Belen Garijo, member of the Executive Board of Merck and CEO Healthcare, when presenting Professor Lunenfeld with the Merck Lifetime Achievement Award.

The research investments through the GFI is core to the innovation strategy of the biopharma business of Merck, and in the quest for increased success rates within fertility treatment. In this year’s GFI, two winning projects were selected from 46 global proposals with the common goal of advancing the fertility field. The GFI was launched in 2009, and is dedicated to transforming innovative translational fertility research projects into actual solutions with the aim to improve fertility treatment outcomes. Merck proudly announced the 2017 GFI awardees during the ceremony:

  • Endometrial Notch pathway as a novel target for improving implantation efficiency; Luisa Campagnolo, PhD
  • Pharmacogenetic algorithm for individualized controlled ovarian stimulation (iCOS) in assisted reproductive technology cycles; Caio Parente Barbosa, MD, PhD, MS and Matheus Roque, MD

About the Grant for Fertility Innovation (GFI) 

Merck announced the initiation of the GFI program in 2009 to support the advancement of science and innovative technologies in the fertility field. This grant is awarded every year to translational research projects that can potentially improve baby birth rate for the benefit of the patients. Each project is blinded and evaluated by a jury of experts according to five criteria: support to increase baby birth rate; innovative research; scientific rationale; feasibility and practical utility.

For further information about the GFI and how to apply for next year’s grants, please visit: http://www.grantforfertilityinnovation.com

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck 

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of EUR15.0 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Contact:
Dr. Raphaela Farrenkopf
+49-6151-72-2274

(Logo: http://photos.prnewswire.com/prnh/20160913/406891LOGO )

PRNews

PAVIGYM: New Fitness Model Unveiled in the UK – PRAMA to be Introduced at Harbour Club Kensington

LONDON, July 4, 2017 /PRNewswire/ — The international fitness training concept PRAMA has announced its arrival in London this month, with its debut studio at the Harbour Club Kensington.

PAVIGYM is the company behind the new concept. CEO of PAVIGYM and creator of PRAMA, Marcos Requena describes the concept:

“No treadmills. No rower. No exercise bike. PRAMA combines great instructors, light and music with workouts designed for training strength, speed, agility and more,” he said. “Interactive screens, pressure sensitive floors and walls and lighting combinations, it tracks heart rate, times your sprints and interacts with you.”

But Mr Requena affirms that it is not all fun and games. For Harbour Club Kensington, Sinead Johnson says: “Harbour Club Kensington is the first club in London to offer a new concept in fitness: PRAMA. PRAMA allows us to recreate different experiences and signature programmes for everyone to enjoy in a single space.”

Jennifer Coccia is Fitness Director at Asphalt Green in New York City and their PRAMA studio, branded AG6. Jennifer describes the merit of the PRAMA method: “We chose PRAMA because depending on how you program the system, it can be for beginners to fitness or our elite athletes. For the athlete side, the reaction-time training is hugely valuable to us, because that is a very difficult component to train outside of a competition. It was important for us to be all-inclusive in this space right through to kids too and we use this concept when training our competitive youth teams; we have seen great results in their performance both on and off the field.”

ABOUT PAVIGYM

PAVIGYM is dedicated to the innovative design of flooring and interactive solutions for the global fitness industry.

Established in the 1960s producing high performance athletic soling, by 1996, PAVIGYM was the world’s first premium flooring company, combining traditional manufacturing with cutting-edge technology.

The evolution of PAVIGYM’s flooring technology continued and in 2008, PAVIGYM was the first company to introduce floor markings into the fitness arena. In-house advances in software capabilities led to the creation of a second industry-first in 2012: PAVIGYM interactive flooring solutions. With applications beyond the floor, PAVIGYM went 360 with this know-how in 2014 introducing PRAMA: a combination of LED enriched stations, pressure sensitive floors and walls, different lighting options controlled at the touch of a button, custom-built to any space.

With a 90-strong team based out of PAVIGYM’s headquarters in Alicante, Spain, six running satellite offices across the globe and 65 distributors representing 93 countries, more than 100 members of the team join in pursuit of a common mission: To provide the best combination of performance flooring, interactive technology, inspiring designs, and ready-to-use programming, so that whomever the end user may be [body-type, age and level], the experience is wholly engaging and feels as intuitive as child’s play.

Contact: Emma Thornton, TPN, emma@theprojectnetworkand.co +447585415754

Video: https://www.youtube.com/watch?v=XZEQlEK2wsQ

Video: https://www.youtube.com/watch?v=AvUTnhMH9Fo

PRNews

The Chicago School Earns 10 Years Accreditation

LOS ANGELES, July 3, 2017 /PRNewswire-USNewswire/ — The Chicago School of Professional Psychology (TCSPP), a nonprofit, private university devoted exclusively to psychology, and behavioral health services, has been granted reaffirmation of accreditation for 10 years by the WASC Senior College and University Commission (WSCUC), a regional accrediting agency serving higher education institutions.

WSCUC determines accreditation through a rigorous process that “assesses the academic quality and educational effectiveness of institutions.” WSCUC  Focusing on student success, institutional structure, processes and resources, the WSCUC Standards of Accreditation consists of four standards of which institutions must be able to demonstrate they are in substantial compliance:

  • Defining institutional purposes and ensuring educational objectives
  • Achieving educational objectives through core functions
  • Developing and applying resources and organizational structures to ensure quality and sustainability
  • Creating an organization committed to quality assurance, institutional learning and improvement

“This achievement is a testament to the excellence of our programs and how our graduates are uniquely positioned to enact positive change in the world,” said President Michele Nealon, Psy.D. “The accreditation process is a comprehensive one, made even more rigorous by the application of it on all of our campuses. The diligent dedication of our staff, faculty and students to our mission and vision has made this possible.”

The Chicago School has been regionally accredited by WSCUC since 2011. The institution’s doctorate in clinical psychology programs at its Chicago and Washington, D.C. campuses are programmatically accredited by the American Psychological Association.

About The Chicago School of Professional Psychology
Founded in 1979, The Chicago School of Professional Psychology (TCSPP) is a nonprofit, private university devoted exclusively to psychology, and behavioral health services. The Chicago School is an affiliate of TCS Education System, a nonprofit system of colleges advancing student success and community impact. The university serves nearly 4,300 students across campuses in Chicago; Southern California (Los Angeles, Irvine and San Diego); and Washington, D.C., as well as through online programs. The Chicago School is accredited by the WASC Senior College and University Commission, (WSCUC), and its Clinical Psychology Doctoral programs in Chicago and Washington, D.C. are accredited by the American Psychological Association. With more than 20 graduate degree programs, thousands of hours of real-world training, and a wealth of international opportunities, TCSPP is the leader in professional psychology education. To learn more, visit www.thechicagoschool.edu

MEDIA CONTACT: Lisa Riley
312.410.8963
lriley@thechicagoschool.edu

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-chicago-school-earns-10-years-accreditation-300483097.html

SOURCE The Chicago School of Professional Psychology

Related Links

http://www.thechicagoschool.edu

PRNews

Endo Completes Divestiture of Litha Healthcare Group

DUBLIN, July 3, 2017 /PRNewswire/ — Endo International plc (NASDAQ: ENDP) today announced that it has completed the previously announced divestiture of its South African based operations, Litha Healthcare Group, to Acino Pharma AG. In February 2017, Endo announced that, following a comprehensive strategic assessment and asset review, the Company determined that Litha no longer aligned with its strategy and was not considered a core asset. 

At closing, Endo received approximately $100 million in cash (after giving effect to cash and net working capital purchase price adjustments) and may receive up to an additional $11 million in contingent consideration. During the fourth quarter of 2016, Endo recorded pre-tax impairment charges of approximately $150 million in order to write-down Litha’s net assets to their estimated fair value less cost to sell.

“Litha has a talented team and we appreciate all the contributions they have made to our Company,” said Paul Campanelli, President and CEO of Endo. “We believe that Acino’s presence in emerging markets makes Litha a good addition to their organization and we wish them both continued success.” 

About Endo International plc
Endo International plc (NASDAQ: ENDP) is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.

About Acino Pharma AG
Acino develops, manufactures and markets high-quality pharmaceuticals for the benefit of patients in over 85 high potential emerging markets in the Middle East, Africa, the CIS region, and Latin America.  Acino is headquartered in Zurich Switzerland.  For additional information go to www.acino.swiss.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements,” including, but not limited to, statements by Mr. Campanelli, within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,” “look forward,” “intend,” “guidance,” “future” or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption “Risk Factors” in Endo’s Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect Endo’s future financial results and could cause Endo’s actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE Endo International plc